"Yangtze River Drifting Bottle" Online Forum | Rolling the Yangtze River with the "letter", Haohao gentleman's "low" singing

*For medical professionals for reading reference

At 19:00 on the evening of July 10th, waiting for the lucky you to go on stage, boiled wine, talk about the diagnosis and treatment of breast cancer in common!

"Yangtze River Drifting Bottle" is a social academic project initiated by the well -known breast cancer academic organization of the Yangtze River Academic Tape (YBCSG): before the meeting, we will capture the "academic drift bottle" of the latest hot topics of breast cancer, through social networking The new form of the media shares academic views and professional circles. In the conference, we will invite the colleagues of the Yangtze River academic belt to participate together to conduct multi -dimensional inventory, respect the discussion, and talk about it. , To help the discussion of academic experience exchanges and hot topics, to improve the level of diagnosis and treatment, and promote the standardized diagnosis and treatment of breast cancer.

From June 3rd to 7th, 2022, the annual conference of the American Clinical Oncology Society (ASCO) in 2022 arrived, and it was an academic feast for the majority of clinical workers. Among them, another "breaking circle" research in the field of breast cancer-Destiny-Breast04 III Studies evaluated the new type of antibody couplet drug (ADC) T-DXD for the treatment of HER2 low-expression metastatic breast cancer patients (HER2 IHC2+ The effect of /iSH-, IHC1+). The results show that regardless of the state of hormone receptor, the T-DXD treatment group has no progressive survival and overall survival period. And whether the patient has been treated with CDK4/6 inhibitors in the past and whether there are internal organs metastasis can benefit from T-DXD treatment. Destiny-Breast04 studied the new "milestone" of HER2 negative breast cancer treatment.

As the "Academic Voice" brought by the ASCO conference, the first online forum "ASCO Essence-Her2 low expression therapy" (ASCO HIGHLIGHT-RIERING HER2-LOW BC ) If it arrives, it will be held on the line at 19:00 on July 10.

From now until July 9 24:00, you can pass

- END -